El producto candidato GI-5005 contra el VHC de GlobeImmune mejora la respuesta virológica sostenida contra del 10 por ciento, demostrando su potencial para convertirse en la primera vacuna terapéutica contra el VHC
15. April 2010 13:00 ET
|
GlobeImmune
LOUISVILLE, CO--(Marketwire - April 15, 2010) -
GlobeImmune, Inc. anunció hoy los datos finales de la fase 2b de GI-5005, el producto candidato Tarmogen(R) bajo investigación de la...
GlobeImmune Announces Presentations of GI-5005 Phase 2b Data at EASL 2010 Meeting
17. März 2010 16:12 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - March 17, 2010) - GlobeImmune Inc. today announced that three abstracts related to GI-5005, the company's hepatitis C (HCV) product candidate, have been accepted...
GlobeImmune Announces $17.5 Million Series E Financing
19. Januar 2010 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - January 19, 2010) - GlobeImmune Inc., a company developing novel
therapies for patients with cancer and infectious diseases, today announced
a Series E Preferred Stock...
GlobeImmune's Hepatitis C Therapeutic Vaccine Combined With Standard of Care Increases End of Treatment Response Rate by 15%
02. November 2009 08:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - November 2, 2009) - GlobeImmune Inc. will present Phase 2b data
today at the 60th Annual Meeting of the American Association for the Study
of Liver Diseases (AASLD)...
GlobeImmune Announces Late-Breaker Presentation of GI-5005 Treatment Response Data at AASLD 2009 Meeting
06. Oktober 2009 07:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - October 6, 2009) - GlobeImmune Inc. today announced that a late
breaking abstract related to GI-5005, its investigational hepatitis C virus
(HCV) product candidate, has...
GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance
15. Mai 2009 07:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO and SUMMIT, NJ--(Marketwire - May 15, 2009) - GlobeImmune, Inc. and Celgene
Corporation (NASDAQ: CELG) today announced a worldwide strategic
collaboration focused on the discovery,...
GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 Percent in Phase 2 Clinical Trial
24. April 2009 01:59 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - April 24, 2009) - Twelve-week Phase 2 clinical trial data show
that patients treated with GI-5005, GlobeImmune's targeted molecular
immunogen (Tarmogen®) for the...
GlobeImmune Initiates Phase 1 Clinical Trial With NCI in CEA Over-Expressing Cancers
16. April 2009 08:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - April 16, 2009) - GlobeImmune, Inc. today announced the
initiation of a Phase 1 clinical trial to investigate the safety and
tolerability of a new Tarmogen, GI-6207, in...
GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial
01. November 2008 11:00 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwire - November 1, 2008) - Four-week Phase 2 clinical trial data show
that GI-5005, GlobeImmune's hepatitis C virus (HCV) targeted molecular
immunogen (Tarmogen®), doubled...
GlobeImmune HCV Phase 2 Four-week Clinical Trial Data for GI-5005 to Be Highlighted at the AASLD President's Press Conference
28. Oktober 2008 08:00 ET
|
GlobeImmune Inc.
LOUISVILLE, CO--(Marketwire - October 28, 2008) - GlobeImmune Inc. today announced that
four-week data from the on-going Phase 2 clinical trial for GI-5005, the
Company's therapeutic vaccine...